Home > Boards > US Listed > Biotechs >

ImmunoTech (AIM)

AIM RSS Feed
Add AIM Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 5/1/2022 4:06:02 PM - Followers: 60 - Board type: Free - Posts Today: 0




 

About AIM ImmunoTech

 
 

AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers,
as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids
and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.

AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3).
Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment)
or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.

We operate a 30,000 sq. ft. facility in New Brunswick, NJ with the objective of producing Ampligen® and Alferon®.
We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and
expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.

https://aimimmuno.com/blog/

CEO Roadshow Interviews Hemispherx Thomas K. Equels

April 4th, 2019

CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down with Mike Elliot of CEO Roadshow to provide an update on everything the company is working at [...]

IM ImmunoTech Reaches Deal with Japan’s National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus

Introducing You to the First Ampligen Quarterly Update

March 25th, 2019

Introducing You to the First Ampligen Quarterly Update Today we announced significant progress in our Ampligen pancreatic cancer program and our multiple Ampligen plus checkpoint blockade immuno-oncology programs. We also announced the [...]

March 9th, 2020

AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus
On March 9 th we announced that Japan’s National Institute of Infectious [...]

https://aimimmuno.com/all-articles/
 

AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19

AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19 SNNLive caught up with Thomas Equels, CEO AIM ImmunoTech Inc. Watch the full video here. [...]

AIM ImmunoTech Announces the National Cancer Institute’s Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers

AIM ImmunoTech Announces the National Cancer Institute's Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers We recently announced [...]

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic We recently announced the AIM ImmunoTech team is working [...]

 

AIM ImmunoTech Reaches Deal with Japan’s National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus

AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus On March 9 th we announced that Japan’s National Institute of Infectious [...]

 


https://aimimmuno.com/
 AIM ImmunoTech is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders
Investor Relations
AIM ImmunoTech is committed to providing up to date information to shareholders, analysts, and potential investors. Get the latest from our blog.

Products
AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a developmental first-in-class drug of large macromolecular RNA molecules.
AIM IMMUNOTECH INC.

Product Candidates Overview

Ampligen®

Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® has in the clinic demonstrated the potential for standalone efficacy in a number of solid tumors.
We have also seen success in increasing survival rates and efficacy in the treatment of animal tumors when
Ampligen® is used in combination with checkpoint blockade therapies.
This success in the field of immuno-oncology has guided our focus toward the potential use of Ampligen®
as a combinational therapy for the treatment of a variety of solid tumor types.
There are currently multiple Ampligen® clinical trials — both underway and planned — at major cancer research centers around the country.
Ampligen ® is also being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP)
approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.

Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). AIM ImmunoTech
is currently sponsoring an expanded access program (EAP) for ME/CFS patients in the U.S.
In August 2016, we received approval of our NDA from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT)
for commercial sale of Ampligen® in the Argentine Republic for the treatment of severe CFS. With regulatory approval in Argentina,
Ampligen® is the world’s only approved therapeutic for ME/CFS.
We continue to pursue our Ampligen New Drug Application, or NDA, for the treatment of CFS with the Food and Drug Administration, or FDA.

Alferon N Injection®

Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory
(resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
Certain types of human papilloma viruses cause GW. AIM ImmunoTech also has approval from ANMAT for the treatment of
refractory patients that failed or were intolerant to treatment with recombinant interferon in Argentina.
We have developed and, with proper funding, will be seeking FDA Pre-Approval Inspection of a high-volume, high-efficiency,
upgraded manufacturing process to allow for the commercial viability of Alferon®.

Pipeline
https://aimimmuno.com/pipeline/




Partnering
https://aimimmuno.com/partnering/

AIM ImmunoTech

Is committed to advancing our technology platforms and product candidates. In order to pursue this goal, AIM ImmunoTech is highly interested in collaborative opportunities including product out-licensing, co-research, co-development, co-promotion, and co-marketing with research institutes, pharmaceutical companies, and biotech companies domestically and internationally.

Ampligen

  • Cancer
    Vaccine Adjuvant
    Broad Spectrum Antiviral
    Traumatic Injury / Burns Immunodeficiency

Alferon

  • Broad Spectrum Antiviral
    Genital Warts
    Anti-Cancer
    Argentina Approval
    Intralesional treatment of external genital warts refractory or recurring
    Treatment patients who initially responded to recombinant interferon alpha, including pegylated interferon alfa, but later treatment failed due to the presence of neutralizing antibodies.

 

Contact Us

Please direct your inquiries regarding business development and licensing opportunities to: info@AIMImmunoTech.com

 


 

2117 SW Highway 484

Ocala, FL 34473

www.hemispherx.net(352) 448-7797


https://www.otcmarkets.com/stock/AIM/disclosure

https://www.otcmarkets.com/stock/AIM/news

https://www.otcmarkets.com/stock/AIM/security
AIM SECURITY DETAILS

Share Structure

Market Cap Market Cap   72,966,225
06/25/2020
 
Authorized Shares
Not Available
 
Outstanding Shares   29,186,490
05/10/2020


https://www.otcmarkets.com/stock/AIM/profile

https://www.otcmarkets.com/stock/AIM/quote

https://www.otcmarkets.com/stock/AIM/overview

https://finviz.com/quote.ashx?t=aim
Book/sh 1.96
Cash/sh 0.84
 
 
Debt/Eq 0.19
 
LT Debt/Eq 0.18
Shs Outstand 32.62M
 
Shs Float 28.77M
Short Float 5.87%







*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.






 
AIM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AIM News: AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference 05/19/2022 04:00:00 AM
AIM News: AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program 05/18/2022 04:00:00 AM
AIM News: AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update 05/16/2022 03:05:00 AM
AIM News: Quarterly Report (10-q) 05/13/2022 12:40:38 PM
AIM News: AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022 05/12/2022 04:05:00 AM
PostSubject
#2015  Sticky Note $AIM this is good AIM ImmunoTech Added to mick 04/18/21 01:31:14 PM
#2041   AIM ImmunoTech Inc (AIM) mick 05/01/22 04:06:02 PM
#2040   AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or crudeoil24 04/25/22 06:57:53 AM
#2039   https://www.otcmarkets.com/stock/AIM mick 03/12/22 04:19:59 PM
#2038   AIM ImmunoTech Inc (AIM) mick 03/12/22 02:22:34 PM
#2037   AIM ImmunoTech Inc (AIM) mick 02/05/22 05:45:00 PM
#2036   https://www.otcmarkets.com/stock/AIM mick 01/02/22 05:15:30 PM
#2035   https://www.otcmarkets.com/stock/AIM mick 12/11/21 05:12:08 PM
#2034   AIM ImmunoTech Inc (AIM) mick 11/06/21 12:48:42 PM
#2033   https://www.otcmarkets.com/stock/AIM mick 10/09/21 01:27:52 PM
#2032   AIM ImmunoTech Inc (AIM) mick 09/22/21 07:44:38 PM
#2031   AIM ImmunoTech Inc (AIM) mick 08/14/21 04:04:57 PM
#2030   Sign this petition for Ampligen approval http://chng.it/ntCkN45ppP Richard2 07/30/21 08:32:14 PM
#2029   Lovely 70g sell maybe news wed carldfw 07/24/21 06:29:34 PM
#2028   AIM seems to have a hand off drug swampboots 07/20/21 08:51:53 PM
#2027   just a question why 9094 shares show up carldfw 07/17/21 08:31:35 PM
#2026   AIM ImmunoTech Inc (AIM) mick 07/10/21 10:57:10 PM
#2025   Im sorry I meant ? under the buy carldfw 06/27/21 05:29:36 PM
#2024   i would say, the product in hand is mick 06/26/21 10:48:42 AM
#2023   What does the ? mean on the buy carldfw 06/25/21 09:12:33 PM
#2022   FDA approved that Alzheimer’s drug that doesn’t work Richard2 06/17/21 11:33:41 AM
#2021   $AIM is headed up in the premarket hours AlphaStockNews 06/14/21 08:25:20 AM
#2020   AIM ImmunoTech Announces Positive Safety Data from the mick 05/26/21 12:02:57 PM
#2019   AIM ImmunoTech Inc (AIM) mick 05/26/21 12:01:55 PM
#2018   www.stockscores.com/chart.asp?TickerSymbol=AIM&TimeRange=180&Interval=d&V mick 05/02/21 07:02:25 PM
#2017   AIM ImmunoTech Inc (AIM) mick 04/19/21 10:40:45 PM
#2016   $AIM this is good AIM ImmunoTech Added to mick 04/18/21 01:31:14 PM
#2015   $AIM this is good AIM ImmunoTech Added to mick 04/18/21 01:31:14 PM
#2014   AIM ImmunoTech Inc (AIM) mick 04/18/21 01:30:00 PM
#2013   AIM ImmunoTech Inc (AIM) mick 04/18/21 01:30:00 PM
#2012   There are 2 new 8K out, aim is hebbeke47 04/10/21 08:36:22 AM
#2010   AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm Goat_1 03/22/21 10:35:52 AM
#2009   $aim $2.44 ^ 0.02 (0.83%) Taurus69 03/21/21 07:23:14 PM
#2008   AIM ImmunoTech to Present at the H.C. Wainwright Goat_1 03/04/21 11:02:18 AM
#2007   Great post thanks carldfw 02/27/21 09:29:17 PM
#2006   EC Form 4: Stewart Appelrouth bought $24,999 worth Goat_1 02/25/21 03:18:15 PM
#2005   $aim $2.47 v -0.02 (-0.80%) Taurus69 02/21/21 06:51:30 PM
#2004   AIM ImmunoTech Inc (AIM) mick 02/21/21 12:15:08 PM
#2003   AIM ImmunoTech Announces Ethics Committee Approval to Commence Goat_1 02/16/21 11:14:00 AM
#2002   AIM ImmunoTech Announces the Expansion of its Pancreatic Goat_1 02/10/21 09:39:40 AM
#2001   AIM ImmunoTech Completes and Closes ATM Facility; Current Goat_1 02/05/21 11:24:40 AM
#2000   * * $AIM Video Chart 02-04-2021 * * ClayTrader 02/04/21 05:40:03 PM
#1999   Yes, Ampligen was not chosen. THey went another chefdaddy70 02/04/21 03:06:46 PM
#1998   Loading up now!$$$ Jess070283 02/04/21 02:29:53 PM
#1997   https://otcbb.swingtradebot.com/equities/AIM N.Y. , NASDAQ mick 01/31/21 11:59:18 PM
#1996   Did any news ever come out of Japan Richard2 01/31/21 01:55:26 AM
#1995   $aim $2.01 ^ 0.02 (1.01%) Taurus69 01/30/21 08:11:17 PM
#1994   AIM ImmunoTech Enters into Agreement for Proposed Intranasal Goat_1 01/29/21 10:28:00 AM
#1993   $aim $1.93 ? 0.0 (0.00%) Taurus69 01/06/21 08:13:13 PM
#1992   AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Goat_1 01/06/21 03:20:36 PM
#1991   https://pennystocks.news/otc/?symbol=AIM mick 01/03/21 12:39:12 PM
PostSubject
Consent Preferences